Company profile
Quince Therapeutics, Inc.
NASDAQ:QNCXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Dexamethasone Sodium Phosphate | approved | — | 2 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01925859 | phase1 | completed | 2013-06-01 | 2013-10-01 | Quince Therapeutics S.p.A. | EryDex Pharmacokinetics in Healthy Volunteers |
| NCT01171807 | phase2 | completed | 2003-07-22 | 2007-05-15 | Quince Therapeutics S.p.A. | Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis |
| NCT06193200 | phase3 | completed | 2024-06-24 | 2025-12-17 | Quince Therapeutics S.p.A. | Evaluate the Neurological Effects of EryDex on Subjects With A-T |
| NCT02770807 | phase3 | completed | 2017-03-02 | 2021-05-13 | Quince Therapeutics S.p.A. | Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients |
| NCT01255358 | phase2 | completed | 2011-02-01 | 2011-09-01 | Quince Therapeutics S.p.A. | Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients |
FDA applications (0)
No records yet.